Company intelligence / Profile preview
CNPharm
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
CNPharm has demonstrated in vivo that their Niclosamide formulations (oral and injectable) sustain blood levels above the antiviral IC50/IC100 for >12–24 hours in animal models; as of mid-2021, they were preparing for clinical trials, but no human clinical data reported yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeDrug delivery system
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hyundai Bioscience (parent/major shareholder)Knotus (non-clinical CRO provider for animal studies)[2]
Beyond the preview
Go deeper on CNPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNPharm.